R&D expenses for the quarter were $53 million, an increase of 3% over the prior-year quarter or on a constant currency basis, an increase of 4%.
This technology is important to our customers, to their patients, as well as to our internal SaaS business and our core sleep apnea business, driving both patient engagement and better outcomes, as well as revenue growth.
The importance of respiratory medicine, the importance of digital health and the importance of healthcare delivered outside the hospital, those three trends just got accelerated, and they're here to stay.
